Literature DB >> 20469339

Gold or penicillamine?

R C Offer.   

Abstract

The recent approval of penicillamine (Cupramine) for use in rheumatoid arthritis has given the physician another remission-inducing drug for this disease. A thorough understanding of penicillamine's administration and toxicity is necessary before the physician begins to use it. Although its efficacy is similar to gold, side effects are considerably more diverse, and longterm side effects require further assessment. This article reviews the clinical use of gold and penicillamine and the factors which may influence the choice of one drug over the other in a given patient.

Entities:  

Year:  1981        PMID: 20469339      PMCID: PMC2538655     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  9 in total

1.  Treatment of palindromic rheumatism with D-penicillamine.

Authors:  E C Huskisson
Journal:  Br Med J       Date:  1976-10-23

Review 2.  Penicillamine and wound healing in rheumatoid arthritis.

Authors:  B M Ansell; H Moran; G P Arden
Journal:  Proc R Soc Med       Date:  1977

3.  Response of rheumatoid arthritis with leukopenia to gold salts.

Authors:  J D Gowans; M Salami
Journal:  N Engl J Med       Date:  1973-05-10       Impact factor: 91.245

4.  Chrysotherapy in psoriatic arthritis. Efficacy and toxicity compared to rheumatoid arthritis.

Authors:  B B Dorwart; E P Gall; H R Schumacher; R E Krauser
Journal:  Arthritis Rheum       Date:  1978-06

5.  Interaction of D-penicillamine with gold salts: in vivo studies on gold chelation and in vitro studies on protein binding.

Authors:  P Davis; D Barraclough
Journal:  Arthritis Rheum       Date:  1977 Sep-Oct

6.  The effect of penicillamine on the laboratory parameters in rheumatoid arthritis.

Authors:  I A Jaffe
Journal:  Arthritis Rheum       Date:  1965-12

7.  Adverse effects of D-penicillamine in rheumatoid arthritis.

Authors:  H B Stein; A C Patterson; R C Offer; C J Atkins; A Teufel; H S Robinson
Journal:  Ann Intern Med       Date:  1980-01       Impact factor: 25.391

8.  Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs.

Authors:  G S Panayi; P Wooley; J R Batchelor
Journal:  Br Med J       Date:  1978-11-11

9.  A controlled trial of D-penicillamine therapy in primary biliary cirrhosis.

Authors:  S Jain; P J Scheuer; S Samourian; J O McGee
Journal:  Lancet       Date:  1977-04-16       Impact factor: 79.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.